Becton Dickinson upgraded by Piper Sandler with a new price target
$BDX
Medical/Dental Instruments
Health Care
Piper Sandler upgraded Becton Dickinson from Neutral to Overweight and set a new price target of $290.00 from $260.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2024 | $255.00 → $275.00 | Neutral → Buy | Citigroup |
| 5/30/2024 | $274.00 | Buy | Goldman |
| 7/24/2023 | $305.00 | Mkt Perform → Outperform | Raymond James |
| 5/30/2023 | $295.00 | Overweight | Morgan Stanley |
| 5/5/2023 | $260.00 → $290.00 | Neutral → Overweight | Piper Sandler |
| 4/12/2023 | $304.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 1/3/2023 | $250.00 → $290.00 | Neutral → Buy | BofA Securities |
| 12/12/2022 | $221.00 → $250.00 | Sell → Neutral | Citigroup |
The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.
- Reuters
Embecta Corp (NASDAQ:EMBC), a manufacturer of disposable insulin pen needles and syringes, is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson and Company (NYSE:BDX). The medical technology company, which supplies approximately 8 billion syringes and needle pens annually across more than 100 countries, has engaged advisers from Centerview Partners to explore a sale. Embecta’s share price has plummeted nearly 70% since its April 2022 spin-off, leaving the Nasdaq-listed firm valued at $2.1 billion. The decline is attributed to several factors, including the impact of GLP-1 drugs such as Novo Nord
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa
For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply
Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /CNW/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /PRNewswire/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
Citigroup upgraded Becton Dickinson from Neutral to Buy and set a new price target of $275.00 from $255.00 previously
Goldman initiated coverage of Becton Dickinson with a rating of Buy and set a new price target of $274.00
Raymond James upgraded Becton Dickinson from Mkt Perform to Outperform and set a new price target of $305.00
BROWNSVILLE, Texas, Nov. 20, 2024 /PRNewswire/ -- A first of its kind Human Papillomavirus (HPV) self-collection screening pilot program aimed at improving cervical cancer screening in underserved communities has officially launched in Texas. HPV is the cause of virtually all cervical cancers. The study is being conducted at Su Clinica, a Federally Qualified Health Center (FQHC) with locations in Brownsville, Harlingen, Raymondville, and Santa Rosa, Texas, together with researchers at The University of Texas MD Anderson Cancer Center. This study will evaluate the implementatio
FRANKLIN LAKES, N.J., Nov. 19, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 10:50 am Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports t
Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organicQ4 GAAP and adjusted diluted EPS from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectivelyFY24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organicFY24 GAAP and adjusted diluted EPS from continuing operations of $5.93 and $13.14 grew 16.3% and 7.6%, respectivelyFY24 cash from continuing operations grew 28.5% to $3.8 billion and Free Cash Flow grew 47.4% to $3.1 billion, increasing $0.9 billion and $1.0 billion since the prior year, respectively
Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organicQ4 GAAP and adjusted diluted EPS from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectivelyFY24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organicFY24 GAAP and adjusted diluted EPS from continuing operations of $5.93 and $13.14 grew 16.3% and 7.6%, respectivelyFY24 cash from continuing operations grew 28.5% to $3.8 billion and Free Cash Flow grew 47.4% to $3.1 billion, increasing $0.9 billion and $1.0 billion since the prior year, respectively
FRANKLIN LAKES, N.J., Nov. 7, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of $1.04 per common share, an increase of 9.5% from the previous quarter. The dividend will be payable on December 31, 2024 to holders of record on December 9, 2024. The indicated annual dividend rate for fiscal year 2025 is $4.16 per share. "This is the 53rd consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This inc
Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision toolsCombination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilitiesBusiness renamed as BD Advanced Patient Monitoring, will be based in Irvine, Calif. and become part of BD Medical segmentKatie Szyman will continue to lead BD Advanced Patient Monitoring as worldwide presidentFRANKLIN LAKES, N.J., Sept. 3, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technolo